Condition: Ovarian Carcinosarcoma · Uterine Carcinosarcoma · Sponsor: Australia New Zealand Gynaecological Oncology Group
The EPOCH study population is patients with tubo-ovarian carcinosarcoma or uterine carcinosarcoma with evidence of recurrence or progression. The study aims to determine the activity of eribulin as a single agent and the combination of eribulin and pembrolizumab as measured by clinical benefit rate (CBR) at 12 weeks. Additionally, the study aims to establish whether high mobility group A2 (HMGA2) protein expression is a good functional biomarker to predict response to eribulin and pembrolizumab.
This description comes directly from the study's public registry record.
Clare Scott, AM MB BS PhD · +61 3 9345 2350 · scottc@wehi.edu.au
John Andrews · +61 2 8071 4881 · EPOCH@anzgog.org.au
Always discuss trial participation with your own doctor first.
| Prince of Wales Hospital | Randwick, New South Wales, Australia | Recruiting |
| Royal Brisbane and Women's Hospital | Herston, Queensland, Australia | Recruiting |
| Monash Health | Clayton, Victoria, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| Princess Margaret Hospital | Toronto, Ontario, Canada | Recruiting |
| Imperial College London | London, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05619913